Replies to post #22177 on Ariad Pharmaceuticals Inc fka ARIA

[vidpok45]

Treatment naive being one of the four cohorts if I am not mistaken in phase 2. Will LDK 378 run a similar trial in treatment naive patients which would provide, as you said, a point of differentiation versus 113. 802's trial, I believe , is on patients who have not had other ALK inhibitors.

[Bxofscidad]

Great point Don



A very well taken point Don, as I believe that I read that LDK378, had little or no effect on naive patients.


Barry